According to the Centre for Medicines Research International, new drug development studies are being conducted to an ever-greater extent in non-core countries. By providing an extra £100 million per year and establishing the UK Clinical Research Collaboration the government has recognised the need to strengthen clinical research in the UK. .
Like other leading pharmaceutical companies, Novartis recognises that successful trials provide the earliest evidence to support the launch of new medicines and that to include the UK in the development programme requires reliable patient recruitment.
To support this need, BioPharma Intelligence Services is commissioned to deploy its ground breaking combination of geospatial data, demographic analysis, and population targeting tools to support the time-, resource-, and cost-efficient completion of clinical studies. The first stage in an ongoing programme has now been completed.
BioPharma Intelligence Services makes the effective identification of potential patient populations easier, quicker and cheaper. By aggregating and visualizing key data, BioPharma Intelligence Services creates information that enables managers to make better decisions.
“We aim to identify investigators on the basis of the potential populations within their catchment zones” said the Clinical Project Manager at Novartis “and anticipate that investigators can then be supported to meet patient recruitment goals more efficiently”.
The Pharmaceutical Industry Competitiveness Task Force identified the three main parameters used by international companies when deciding where to place clinical studies: speed, quality, and cost.
Each decision on how much research to place within the UK depends on a judgement about overall cost-effectiveness. Head of Clinical Operations at Novartis UK commented, “Novartis are keen to attract clinical development funds to the UK by demonstrating improvements in these drivers, particularly speed and cost. BioPharma Intelligence Services has been commissioned to improve the efficient conduct of UK studies through enhanced investigator selection and patient recruitment performance”.
For further information, contact Alan Needham, Principal Consultant, +44 (0) 771 319 1981
BioPharma Practice Ltd; Datum House, Roentgen Road, Basingstoke, Hampshire RG24 8NG
Notes for Editors: BioPharma Intelligence Services is a trading division of BioPharma Practice Ltd, a radically new support consultancy for patient and investigator site recruitment and retention. Headquartered in Basingstoke, England, the company has invested significantly in software systems and data to establish a unique proposition for the pharmaceutical industry.
Learn more about us at http://www.biopharmapractice.co.uk/ or Call 0800 612 0749
For more information:
Last updated on: 27/08/2010